The latest report from Future Market Insights sheds light on a promising growth trajectory for the global atrophic vaginitis treatment market, forecasting a robust compound annual growth rate (CAGR) of 8% from 2023 to 2033. Anticipated to expand from a valuation of USD 2.78 billion in 2023 to a substantial USD 6 billion by 2033, stakeholders are enthusiastic about the potential advances and broader adoption of effective treatments to meet the increasing demand.
Atrophic vaginitis, a condition predominantly affecting postmenopausal women, manifests symptoms such as vaginal dryness, itching, and painful intercourse. According to a report by the National Institutes of Health, approximately 50% of women experience vaginal discomfort post-menopause, with 10-40% diagnosed with atrophic vaginitis. This underscores the significant patient population in need of effective and sustainable treatment options.
Get Sample Copy of Latest Reports: https://www.futuremarketinsights.com/reports/sample/rep-gb-16831
Key factors driving the growth of the atrophic vaginitis treatment market include:
- Increasing prevalence of atrophic vaginitis among postmenopausal women.
- Rising awareness about the importance of women’s health and well-being.
- Technological advancements in treatment modalities and drug delivery systems.
- Initiatives by governments and healthcare organizations to improve access to healthcare services for women.
With a burgeoning market and evolving treatment landscape, stakeholders across the healthcare spectrum are poised to capitalize on emerging opportunities and drive innovation in atrophic vaginitis treatment.
Key Takeaways from the Market Study:
- The global Atrophic vaginitis treatment market is expected to grow with an 8% CAGR during 2023 to 2033.
- By therapy type, Estrogen based therapy are expected to hold 53% of the market share in 2023 for Atrophic vaginitis treatment market.
- North America is expected to possess 48% market share for Atrophic vaginitis treatment market in 2023.
- Europe Atrophic vaginitis treatment market size is expected to possess 43% market share in 2023.
“The atrophic vaginitis treatment market is revolutionizing women’s health by providing effective solutions to a common condition that affects millions of women worldwide. With the increasing prevalence of the condition, the market is expected to grow significantly in the coming years. Despite the challenges faced by the industry” states an FMI analyst
Request Customization Available: https://www.futuremarketinsights.com/customization-available/rep-gb-16831
Competitive Landscape:
Key players in the atrophic vaginitis treatment are Shionogi, Duchesnay, Hormos Medical, QuatRx Pharmaceuticals, Pantarhei Bioscience, Mithra Pharmaceuticals, AMAG Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc, Theramex, Endoceutics, Inc.
- Shionogi is a pharmaceutical company that has developed a treatment for atrophic vaginitis called Intrarosa (prasterone). Intrarosa is a vaginal insert that contains the hormone dehydroepiandrosterone (DHEA), which is converted into estrogen in the body.
- Bayer HealthCare Pharmaceuticals Inc, a key player in the atrophic vaginitis treatment market is focusing on developing treatments for the ailment by researching and investing in developing therapies.
Key Segments Profiled in the Atrophic Vaginitis Treatment Industry Survey:
Diagnosis:
- Pelvic exam
- Urine test
- Acid balance test
Treatment:
- Vaginal moisturizers
- Water-based lubricants
Therapy Type:
- Estrogen based drugs
- Non-estrogen based drugs
Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
A Comprehensive Full Report: https://www.futuremarketinsights.com/checkout/16831
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube